JOJackson Orem

Jackson Orem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jackson Orem has a total of 309 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cancer outcomes in low and middle-income countries: the role of clinical, sociodemographics, and public funding as drivers

    by Bridget S Angucia, Nixon Niyonzima, Ezra Anecho, Daniel Biyinzika, Bashir Ngobi, Juliet Nabyonga, Alfred Jatho, Jackson Orem

  • Open Access

    Independent cancer research in low- and middle-income countries: why it matters and how to build it

    by Oscar Arrieta, Eduardo Rios-Garcia, Cittim B Palomares-Palomares, Alejandro Aranda-Gutierrez, Regina Barragan-Carrillo, Carlos H Barrios, Andrés F Cardona, Luis Corrales, Narjust Florez, Juan-Manuel Hernandez-Martinez, et al.

    By 2030, an estimated 75% of cancer deaths will occur in low- and middle-income countries (LMICs). Weak surveillance systems and limited research infrastructure often hide the true magnitude of this burden. Thus, independent, locally led research is essential for generating high-quality data, addressing regional disease patterns, and informing context-specific strategies for cancer control. Low national investment, heavy reliance on industry-sponsored trials, and a scarcity of trained clinician scientists hinder independent cancer research in LMICs. In this narrative review, we synthesize the published literature and present a descriptive analysis of oncology trials registered on ClinicalTrials.gov (accessed July 2025), categorized by country, funding source, and tumor site and normalized to disease burden, drawing on illustrative examples from Africa, Asia, and Latin America. We highlight the transformative impact of context-sensitive research initiatives, explore disparities in sponsorship by country and tumor type, and outline ways to strengthen the research infrastructure. These include the establishment of population-based cancer registries, regional funding mechanisms, streamlined regulatory frameworks, and workforce development through formal research training and protected time. Finally, we propose strategies to enhance international collaboration and amplify LMIC participation in setting global cancer research priorities.

  • Applying Quality Oncology Practices in Africa: Lean Implementation, Real Impact

    by Naghib Bogere, David Mwiine, Judith Asasira, Bridget Sharon Angucia, Jacinta Ojia Ambaru, Sandra Awino, Majoreen Twinokusiima, Salustia Aloyce Bugingo, Caroline Nakidde, Barbra Natukunda, et al.

    BACKGROUND: In many low- and middle-income countries, expanding access to cancer services has been a major priority. Yet, patient outcomes increasingly depend not only on whether services exist but on how care is organized, documented, and coordinated within overstretched systems. ASCO's Quality Oncology Practice Initiative (QOPI) has shown that structured quality measurement is feasible in resource-limited settings (RLSs), but less attention has been given to how such frameworks can be sustained without adding pressure to already burdened clinical teams. OBJECTIVE: To describe how the ASCO QOPI Resource-Limited Setting (RLS) track, implemented through a lean, stepwise approach, can generate real and sustained institutional improvements in a resource-constrained oncology setting in sub-Saharan Africa. METHODS: Drawing on implementation experience across African oncology programs, this analysis applies a lean lens. Lean is used here as an approach that focuses on simplifying processes, reducing unnecessary steps, and introducing changes in stages. The analysis examines how QOPI RLS was introduced in a stepwise fashion and integrated into routine care. The three-tier structure is analyzed as a sequencing strategy that stabilizes core processes before expanding measurement to more complex domains. Operational examples illustrate how QOPI evolved from a documentation exercise into an embedded governance tool. RESULTS: A staged and lean-informed implementation transformed QOPI from a reporting framework into an organizing system for care delivery. Initial focus on essential processes such as documentation and treatment planning established a reliable baseline. Subsequent expansion made previously hidden gaps in safety, coordination, and continuity of care visible, allowing targeted improvements without overloading clinical workflows. Over time, quality activities became embedded within routine practice, supporting more consistent delivery of systemic therapies and strengthening institutional capability. As systems matured, these processes also created a foundation for more complex functions, including coordination across the patient pathway and readiness for clinical trial implementation. CONCLUSION: Structured, stepwise quality approaches can strengthen oncology care in RLSs by improving the reliability of core processes. This offers a practical pathway for applying global standards and improving day-to-day care across diverse health systems.

  • Open Access

    Utilizing Process Mapping as a Framework for Identifying and Prioritizing Barriers to Antibiotic Delivery in Resource-limited Settings

    by Elizabeth A Gulleen, Johnblack Kabukye, Maiya Grace Block Ngaybe, Fred Bwogi, Constance Namirembe, Catherine Liu, Jackson Orem, Warren Phipps

    In resource-limited settings, healthcare providers face unique structural barriers to antibiotic delivery. Process mapping (PM) is a low-cost, low-technology approach used to understand the antibiotic delivery process and systematically identify barriers to timely antibiotic initiation. In this paper, we will use a 5-phase PM framework to provide the readers with a guide to developing antibiotic delivery process maps, identifying barriers to antibiotic delivery, and prioritizing the order in which these barriers should be addressed. We will then use our experience at the Uganda Cancer Institute in Kampala, Uganda as a case study to describe how we used PM to identify barriers to antimicrobial delivery for patients with neutropenic fever. We will also provide information about how to use low-cost supplies and open-access software to develop and analyze the process map. By the end of the paper, the reader will have the necessary tools to develop and analyze their own antibiotic delivery process maps. This will allow the reader to systematically identify barriers to antimicrobial delivery and understand how to prioritize which barriers to address using targeted interventions.


  • Impact of Waiting Time and Treatment Duration on Short-Term Outcomes for Patients With Locally Advanced Cervical Cancer at the Uganda Cancer Institute: The Challenges in Resource-Limited Settings

    by Awusi Kavuma, Solomon Kibudde, Daniel Mukasa Kanyike, Israel Luutu, Jackson Orem

    PURPOSE: Cervical cancer remains a significant public health burden, especially in sub-Saharan Africa. The waiting time and treatment duration are key indicators of quality in oncology care, and guidelines recommend that chemoradiation for patients with locally advanced cervical cancer (LACC) should be completed within 8 weeks. This study aimed to quantify waiting times and treatment durations for LACC at the Uganda Cancer Institute and identify bottlenecks in the radiotherapy treatment pathway. MATERIALS AND METHODS: This prospective study involved 196 patients with LACC. The department’s treatment protocol for LACC allows either conventional fractionated radiotherapy (CFRT) at 50 Gy/25# or hypofractionated radiotherapy (HFRT) at 45 Gy/15#, followed by brachytherapy at 24 Gy/3#. Nine key treatment milestones were documented from diagnosis to brachytherapy completion. The impact of social determinants of health on waiting times was analyzed. Responses were assessed 6 months after treatment completion. RESULTS: Patients spent a median delay time of 41 days and a median waiting time of 88 days. The median external beam radiation therapy duration was 40 days for CFRT, compared with 24 days for HFRT. The median waiting time before initiating brachytherapy was 40 days, leading to an overall treatment duration of 85 days for CFRT and 66 days for HFRT. Only 18% of patients on CFRT and 37% of patients on HFRT completed within timelines. The proportions of patients with either waiting times or treatment duration of ≤8 weeks who had complete responses were comparatively greater than those who started treatments after >8 weeks. CONCLUSION: Only 25% completed treatment within the recommended timelines. The long waiting time for brachytherapy makes it impossible to finish within timelines. Strategies to expedite access to brachytherapy are necessary to enhance radiotherapy quality.

  • Open Access

    Supplementary Figures from DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features

    by Nicole Thomas, Carlos A. García-Prieto, Kostiantyn Dreval, Laura K. Hilton, Jeremy S. Abramson, Nancy L. Bartlett, Jeffrey Bethony, Jay Bowen, Anthony C. Bryan, Corey Casper, et al.

    Supplemental Figure 1. Association between genetic alterations and methylation patterns Supplemental Figure 2. Epitypes characteristics and their relation to other lymphomas. Supplemental Figure 3. Comparison of epitype characteristics in relation to EBV status. Supplemental Figure 4. Validation of epitypes using Nanopore sequencing data. Supplemental Figure 5. Selected characteristics of BL epitypes and relative aSHM frequencies in EBV-positive BL. Supplemental Figure 6. GSEA plots for SignatureDB pathways determined to be significantly different between BL epitypes. Supplemental Figure 7. The Cox proportional hazards models accounting for both BL epitype and TP53 mutation status in adult BLs.

  • Open Access

    Supplementary Tables from DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features

    by Nicole Thomas, Carlos A. García-Prieto, Kostiantyn Dreval, Laura K. Hilton, Jeremy S. Abramson, Nancy L. Bartlett, Jeffrey Bethony, Jay Bowen, Anthony C. Bryan, Corey Casper, et al.

    S1. DMRs EBVpos vs CB S2. DMRs EBVneg vs CB S3. Shared DMRs EBV S4. DMRs EBV status S5. Methylation gene corrs EB S6. GO pathways enrichment S7. LPS selected probes S8. Epitype assignment S9. DMRs eptiype S10. DMR gene corrs epitype S11. JASPAR TF results epitype S12. JASPAR TF results EBV S13. aSHM epitype S14. DEG epitpye S15. SignatureDB pathways enrichment

  • Open Access

    Pragmatic Approach to Hepatocellular Carcinoma Diagnosis in High-Incidence, Resource-Limited Settings in Africa

    by Gregory D. Kirk, Sara Nsibirwa, Jim K. Aizire, Redeat L. Assefa, Antonio Bandala-Jacques, Jackson Orem, Tongai Maponga, Moussa Seydi, Gilles Wandeler, Amir Mohareb, et al.

    PURPOSE: Hepatocellular carcinoma (HCC) is common and deadly in sub-Saharan Africa, where advanced imaging techniques, such as computerized tomography and magnetic resonance imaging, are scarce. The purpose of this study was to develop a pragmatic HCC diagnostic strategy for such settings. METHODS: We evaluated standardized protocol-collected data on clinical, ultrasonographic, biochemical, and pathological criteria in a multisite study of 649 suspected HCC cases in Uganda. Participants underwent standardized interviews, clinical assessments, and ultrasound examinations by trained staff with alpha-fetoprotein (AFP) testing at a central laboratory, and pathology was obtained for selected participants. Concordance analysis and percentage-confirmed yield using different HCC case definitions were performed, with survival follow-up as a validation measure. RESULTS: The median age was 45 years, 68% were male, and 45% had chronic hepatitis B infection. Ultrasonographic, biochemical (AFP), and pathological definitions confirmed 91%, 57%, and 17% of clinically defined HCC cases, respectively. The median survival after diagnosis was 46 days. An integrated HCC case definition that combined clinical criteria with one confirmatory test increased the percentage-confirmed yield by 3.7% (ultrasonographic), 37.7% (biochemical), and 77.7% (pathologic) over the clinical definition alone. Yield from AFP or pathology beyond ultrasound was minimal. Survival did not differ appreciably by HCC case definition. This integrated HCC case definition maintained diagnostic rigor while maximizing yield. CONCLUSION: We propose an integrated HCC case definition as a pragmatic, resource-adaptable approach for clinical diagnosis and research in sub-Saharan Africa. This definition can be readily implemented and can support regional collaborative efforts to develop novel diagnostics and improved treatments to ameliorate the heavy HCC burden.


  • Open Access

    DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features

    by Nicole Thomas, Carlos A. García-Prieto, Kostiantyn Dreval, Laura K. Hilton, Jeremy S. Abramson, Nancy L. Bartlett, Jeffrey Bethony, Jay Bowen, Anthony C. Bryan, Corey Casper, et al.

    The genetic subtypes of Burkitt lymphoma have been defined, but the role of epigenetics remains to be comprehensively characterized. We searched genomic DNA from 218 patients across four continents for recurrent DNA methylation patterns and their associations with clinical and molecular features. We identified DNA methylation patterns that were not fully explained by the Epstein–Barr virus status or mutation status, leading to two epitypes described here as HypoBL and HyperBL. Each is characterized by distinct genomic and clinical features including global methylation, mutation burden, aberrant somatic hypermutation, and survival outcomes. Methylation, gene expression, and mutational differences between the epitypes support a model in which each arises from a distinct cell of origin. These results, pending validation in external cohorts, point to a refined risk assessment for patients with Burkitt lymphoma who may experience inferior outcomes. Significance: Burkitt lymphoma can be divided into two epigenetic subtypes (epitypes), each carrying distinct biological, transcriptomic, genomic, and clinical features. Epitype is more strongly associated with clinical and mutational features than the Epstein–Barr virus status or genetic subtype, highlighting an important additional layer of Burkitt lymphoma pathogenesis.


  • Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda

    by Manoj P. Menon, Henry Ddungu, Kelvin R. Mubiru, Scott V. Adams, Jacqueline Asea, Rosemary Namagembe, Prossy Namuli, Joyce Kambugu, Andrea M.H. Towlerton, Camille Puronen, et al.

    PURPOSE: Patients with diffuse large B-cell lymphoma (DLBCL) who are treated in low-resource settings have inferior outcomes compared with those in high-resource settings. Rituximab, an anti-CD20 monoclonal antibody, when combined with chemotherapy, improves overall survival (OS) for DLBCL. However, in part due to the limited availability of infusion centers in low-resource countries, rituximab is rarely used. Subcutaneous rituximab (sqR) is a potential solution; however, its safety and efficacy have not been tested in low-income countries. METHODS: This open-label phase I study enrolled patients 18 years or older with newly diagnosed DLBCL. The first cohort (n = 6) received intravenous rituximab plus CHOP. This cohort received sqR for subsequent cycles. The second cohort (n = 12) received sqR plus CHOP for all cycles. Safety and tolerability were evaluated; secondary outcomes included response rates and treatment completion. RESULTS: Between October 25, 2019, and October 7, 2022, 18 patients, with a median age of 36.5 years, were enrolled; 10 were male, and 10 presented with advanced-stage disease. The most common hematologic toxicity was neutropenia (n = 9, 50%). Fifteen of the 18 participants completed treatment; 14 (93.3%) patients achieved a complete response, and one patient (6.7%) had a partial response. The OS and progression-free survival (PFS) at 12 months were 83% (95% CI, 68 to 100) and 67% (95% CI, 48 to 92), respectively. The OS and PFS at 24 months were 66% (95% CI, 47 to 92) and 67% (95% CI, 48 to 92), respectively. CONCLUSION: As demonstrated in other parts of the world, sqR together with CHOP was safe, well-tolerated, and efficacious among Ugandan patients with DLBCL. The very high OS rates are nearly double those of historical controls and comparable with outcomes expected in resource-rich settings. This study demonstrated the feasibility, safety, and efficacy of sqR-CHOP, increased the research infrastructure in Uganda, and will improve care in other resource-limited settings.